You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Ezetimibe; rosuvastatin calcium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for ezetimibe; rosuvastatin calcium and what is the scope of freedom to operate?

Ezetimibe; rosuvastatin calcium is the generic ingredient in one branded drug marketed by Althera Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ezetimibe; rosuvastatin calcium has eleven patent family members in ten countries.

Summary for ezetimibe; rosuvastatin calcium
International Patents:11
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Clinical Trials: 2
DailyMed Link:ezetimibe; rosuvastatin calcium at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ezetimibe; rosuvastatin calcium
Generic Entry Date for ezetimibe; rosuvastatin calcium*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ezetimibe; rosuvastatin calcium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Samsung Medical CenterPhase 4
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Federal University of São PauloPhase 4

See all ezetimibe; rosuvastatin calcium clinical trials

US Patents and Regulatory Information for ezetimibe; rosuvastatin calcium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-003 Mar 23, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-004 Mar 23, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-001 Mar 23, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-002 Mar 23, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-002 Mar 23, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-001 Mar 23, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ezetimibe; rosuvastatin calcium

Country Patent Number Title Estimated Expiration
Poland 2844233 ⤷  Sign Up
Mexico 365046 FORMULACION DE TABLETA ORAL QUE CONSISTE DE UNA COMBINACION FIJA DE ROSUVASTATINA Y EZETIMIBA PARA EL TRATAMIENTO DE HIPERLIPIDEMIA Y ENFERMEDADES CARDIOVASCULARES. (ORAL TABLET FORMULATION CONSISTING OF FIXED COMBINATION OF ROSUVASTATIN AND EZETIMIBE FOR TREATMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASES.) ⤷  Sign Up
Spain 2802252 ⤷  Sign Up
Mexico 2014013241 FORMULACION DE TABLETA ORAL QUE CONSISTE DE UNA COMBINACION FIJA DE ROSUVASTATINA Y EZETIMIBA PARA EL TRATAMIENTO DE HIPERLIPIDEMIA Y ENFERMEDADES CARDIOVASCULARES. (ORAL TABLET FORMULATION CONSISTING OF FIXED COMBINATION OF ROSUVASTATIN AND EZETIMIBE FOR TREATMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASES.) ⤷  Sign Up
Denmark 2844233 ⤷  Sign Up
European Patent Office 2844233 FORMULATION DE COMPRIMÉ ORAL CONSTITUÉE D'UNE COMBINAISON FIXE DE ROSUVASTATINE ET D'ÉZÉTIMIBE POUR LE TRAITEMENT DE L'HYPERLIPIDÉMIE ET DE MALADIES CARDIOVASCULAIRES (ORAL TABLET FORMULATION CONSISTING OF FIXED COMBINATION OF ROSUVASTATIN AND EZETIMIBE FOR TREATMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASES) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ezetimibe; rosuvastatin calcium

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 03C0028 France ⤷  Sign Up PRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017
0720599 05C0040 France ⤷  Sign Up PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.